[BMJ Publishing Group Ltd and European League Against Rheumatism Annual European Congress of Rheumatology, 14–17 June, 2017 - ()] Oral Presentations - OP0203 Impact of adalimumab serum concentration on efficacy and association between ANTI-DRUG antibodies and serum concentration: 24 week results from a phase III study comparing SB5 (an adalimumab biosimilar) with reference adalimumab in patients with rheumatoid arthritis